drospirenone has been researched along with Body Weight in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.00) | 18.2507 |
| 2000's | 18 (72.00) | 29.6817 |
| 2010's | 5 (20.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dožić, B; Dožić, I; Srebro, D; Vujović, S; Đogo, A | 1 |
| Adeyanju, OA; Olatunji, LA | 1 |
| Apter, D; Beekman, L; Coelingh Bennink, HJT; Foidart, JM; Maillard, C; Mawet, M; Zimmerman, Y | 1 |
| Aksoy, DY; Arusoglu, G; Cinar, N; Koksal, G; Tapan, S; Yildiz, BO | 1 |
| Baihua, D; Caiyan, W; Hongyu, W; Huan, S; Liangdan, T; Meiqing, X; Mulan, R; Qinping, L; Shulan, Z; Wen, D; Xiaomao, L; Xiaoyan, X; Youdi, X; Yufeng, L; Zheng'ai, X; Zhisong, M; Zirong, H; Ziyan, H | 1 |
| Cagnacci, A; D'Alterio, MN; Di Carlo, C; Melis, GB; Neri, M; Orrù, MM; Paoletti, AM | 1 |
| Carranza-Lira, S | 1 |
| El-Samalouti, V; Gerlinger, C; Junge, W; Schaefers, M | 1 |
| Shulman, LP | 1 |
| Buicu, C; Endrikat, J; Gaspard, U; Gerlinger, C; Heithecker, R; Lefebvre, P; Scheen, A | 1 |
| Armbruster, U; Bitzer, J; Meier-Burgoa, J; Schwendke, A; Tschudin, S | 1 |
| Suthipongse, W; Taneepanichskul, S | 1 |
| Foidart, JM | 1 |
| Aubeny, E; Bastianelli, C; Birkhäuser, MH; Bjertnaes, A; Gruber, CJ; Knudsen, T; Lete, I; Lindh, I; Milsom, I; Rokstad, K | 1 |
| Foidart, JM; Genazzani, AR; Palacios, S | 1 |
| Aldrighi, JM; Andrade, RP; Borges, LE; Camargos, AF; Guazelli, C; Isaia, CF; Peixoto, FC; Petracco, A; Yazlle, ME | 1 |
| Fratta, S; Fruzzetti, F; Genazzani, AR; Lazzarini, V; Lello, S; Melis, GB; Minerba, L; Orrù, M; Paoletti, AM; Ricci, C; Sorge, R | 1 |
| Endrikat, J; Fortier, M; Gerlinger, C; Rübig, A; Sandri, M; Schmidt, W | 1 |
| Dombrovicz, N; Foidart, JM; Heithecker, R; Oelkers, W; Welter, A | 1 |
| Parsey, KS; Pong, A | 1 |
| Bouw, GM; Foidart, JM; Gerlinger, C; Heithecker, R; Wuttke, W | 1 |
| Oelkers, W | 1 |
6 review(s) available for drospirenone and Body Weight
| Article | Year |
|---|---|
Drospirenone in HRT?
Topics: Aged; Androstenes; Blood Pressure; Body Weight; Bone Density; Contraindications; Drug Costs; Female; Hormone Replacement Therapy; Humans; Middle Aged; Postmenopause; Practice Guidelines as Topic; Progesterone Congeners | 2009 |
Safety, efficacy and patient acceptability of drospirenone and estradiol in the treatment of menopausal vasomotor symptoms: a review.
Topics: Aged; Androstenes; Blood Pressure; Body Weight; Estradiol; Estrogens; Female; Humans; Lipoproteins; Menopause; Middle Aged; Mineralocorticoid Receptor Antagonists; Patient Acceptance of Health Care; Quality of Life; Treatment Outcome; Vasomotor System | 2009 |
Is [symbol: see text] Yasmin a "truly different" pill?
Topics: Adolescent; Adult; Androstenes; Body Weight; Contraceptives, Oral, Combined; Female; Humans; Mineralocorticoid Receptor Antagonists; Progesterone Congeners; Randomized Controlled Trials as Topic | 2002 |
Added benefits of drospirenone for compliance.
Topics: Androstenes; Body Weight; Contraceptives, Oral; Drug Combinations; Estradiol; Estrogen Replacement Therapy; Female; Humans; Mineralocorticoid Receptor Antagonists; Patient Compliance; Premenstrual Syndrome; Progesterone Congeners; Quality of Life | 2005 |
Advances in hormone replacement therapy with drospirenone, a unique progestogen with aldosterone receptor antagonism.
Topics: Androstenes; Blood Pressure; Body Weight; Drug Combinations; Estradiol; Estrogen Replacement Therapy; Female; Humans; Menopause; Mineralocorticoid Receptor Antagonists; Progesterone Congeners; Randomized Controlled Trials as Topic; Renin-Angiotensin System | 2006 |
The renin-aldosterone system and drospirenone.
Topics: Androstenes; Animals; Blood Pressure; Body Weight; Ethinyl Estradiol; Humans; Natriuresis; Progesterone; Receptors, Steroid; Renin-Angiotensin System; Transcriptional Activation | 2002 |
12 trial(s) available for drospirenone and Body Weight
| Article | Year |
|---|---|
Estetrol combined with drospirenone: an oral contraceptive with high acceptability, user satisfaction, well-being and favourable body weight control.
Topics: Adolescent; Adult; Androstenes; Body Weight; Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Estetrol; Female; Finland; Humans; Intention to Treat Analysis; Mineralocorticoid Receptor Antagonists; Patient Satisfaction; Surveys and Questionnaires; Uterine Hemorrhage; Young Adult | 2017 |
Clinical effect of hormonal replacement therapy with estradiol associated with noretisterone or drospirenone. A prospective randomized placebo controlled study.
Topics: Adipose Tissue; Androstenes; Body Composition; Body Water; Body Weight; Double-Blind Method; Drug Therapy, Combination; Estradiol; Estrogen Replacement Therapy; Estrogens; Female; Hot Flashes; Humans; Insulin Resistance; Middle Aged; Mineralocorticoid Receptor Antagonists; Norethindrone; Postmenopause; Progesterone Congeners; Quality of Life; Treatment Outcome | 2015 |
Effects of menopausal hormone therapy on hemostatic parameters, blood pressure, and body weight: open-label comparison of randomized treatment with estradiol plus drospirenone versus estradiol plus norethisterone acetate.
Topics: Aged; Androstenes; Blood Pressure; Body Weight; Drug Therapy, Combination; Estradiol; Female; Fibrin Fibrinogen Degradation Products; Hemostasis; Humans; Middle Aged; Norethindrone; Protein C | 2009 |
A randomized study over 13 cycles to assess the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on carbohydrate metabolism.
Topics: Adolescent; Adult; Androstenes; Blood Glucose; Blood Pressure; Body Weight; C-Peptide; Carbohydrate Metabolism; Contraceptives, Oral, Combined; Desogestrel; Ethinyl Estradiol; Fasting; Fatty Acids, Nonesterified; Female; Glucose Tolerance Test; Humans; Insulin; Kinetics | 2003 |
[Effects on the quality of life of a new oral contraceptive containing 30 mcg EE and 3 mg drospirenone (Yasmin)].
Topics: Adult; Androstenes; Body Weight; Contraceptives, Oral; Data Interpretation, Statistical; Ethinyl Estradiol; Female; Follow-Up Studies; Humans; Libido; Menstruation; Progesterone Congeners; Quality of Life; Surveys and Questionnaires; Time Factors | 2003 |
An open-label randomized comparative study of oral contraceptives between medications containing 3 mg drospirenone/30 microg ethinylestradiol and 150 microg levonogestrel/30 microg ethinylestradiol in Thai women.
Topics: Adolescent; Adult; Androstenes; Blood Pressure; Body Weight; Contraceptives, Oral, Combined; Ethinyl Estradiol; Female; Humans; Levonorgestrel; Menstrual Cycle; Thailand | 2004 |
Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone.
Topics: Administration, Oral; Adult; Androstenes; Body Composition; Body Weight; Contraceptive Devices, Female; Contraceptives, Oral; Desogestrel; Drug Combinations; Ethinyl Estradiol; Humans; Intrauterine Devices; Menstrual Cycle; Patient Compliance | 2006 |
Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception.
Topics: Adolescent; Adult; Affect; Androstenes; Blood Pressure; Body Fluids; Body Weight; Contraception; Contraceptives, Oral, Combined; Ethinyl Estradiol; Female; Humans; Menstrual Cycle; Premenstrual Syndrome; Progesterone Congeners | 2006 |
The oral contraceptive containing 30 microg of ethinylestradiol plus 3 mg of drospirenone is able to antagonize the increase of extracellular water occurring in healthy young women during the luteal phase of the menstrual cycle: an observational study.
Topics: Adolescent; Adult; Androstenes; Body Composition; Body Water; Body Weight; Contraceptives, Oral, Combined; Electric Impedance; Estrogens; Ethinyl Estradiol; Extracellular Fluid; Female; Humans; Intracellular Fluid; Luteal Phase; Mineralocorticoid Receptor Antagonists; Mineralocorticoids | 2007 |
A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 microg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight.
Topics: Adult; Androstenes; Body Water; Body Weight; Canada; Contraceptives, Oral, Combined; Edema; Ethinyl Estradiol; Female; Humans; Mineralocorticoid Receptor Antagonists; Premenstrual Syndrome; Prospective Studies; Severity of Illness Index; Surveys and Questionnaires | 2007 |
Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.
Topics: Adolescent; Adult; Aldosterone; Androstenes; Angiotensin I; Blood Pressure; Body Weight; Contraceptives, Oral, Combined; Ethinyl Estradiol; Female; Glucose Tolerance Test; Humans; Lipids; Mineralocorticoids; Renin; Renin-Angiotensin System | 1995 |
A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel.
Topics: Adult; Androstenes; Body Weight; Contraceptives, Oral, Synthetic; Desogestrel; Europe; Female; Humans; Menstrual Cycle; Menstruation Disturbances; Pregnancy; Pregnancy Rate; Premenstrual Syndrome; Progesterone Congeners | 2000 |
7 other study(ies) available for drospirenone and Body Weight
| Article | Year |
|---|---|
Effects of continuous-combined oral drospirenone- estradiol on blood pressure, body weight & lipid profile in early menopausal women.
Topics: Adult; Androstenes; Blood Pressure; Body Weight; Cardiovascular Diseases; Cholesterol; Estradiol; Female; Humans; Hypertension; Lipids; Menopause; Menopause, Premature; Middle Aged; Retrospective Studies | 2021 |
Drospirenone-containing oral contraceptives do not affect glucose regulation and circulating corticosterone.
Topics: Androstenes; Animals; Blood Glucose; Body Weight; Contraceptives, Oral; Corticosterone; Drug Combinations; Ethinyl Estradiol; Female; Insulin; Insulin-Secreting Cells; Levonorgestrel; Rats | 2019 |
Basal and meal-stimulated ghrelin, PYY, CCK levels and satiety in lean women with polycystic ovary syndrome: effect of low-dose oral contraceptive.
Topics: Adolescent; Adult; Androstenes; Basal Metabolism; Body Weight; Cholecystokinin; Contraceptives, Oral; Eating; Estrogens; Ethinyl Estradiol; Female; Ghrelin; Humans; Mineralocorticoid Receptor Antagonists; Peptide YY; Polycystic Ovary Syndrome; Prospective Studies; Satiety Response; Young Adult | 2013 |
[Efficacy and safety of a combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 µg in a 24+4-day regimen in China].
Topics: Adolescent; Adult; Androstenes; Body Weight; China; Contraceptives, Oral, Combined; Dose-Response Relationship, Drug; Drug Administration Schedule; Estrogens; Ethinyl Estradiol; Female; Humans; Menstrual Cycle; Menstruation; Mineralocorticoid Receptor Antagonists; Pregnancy; Pregnancy Rate; Treatment Outcome; Uterine Hemorrhage; Young Adult | 2014 |
Safety and efficacy of a new oral contraceptive containing drospirenone.
Topics: Androstenes; Body Weight; Contraceptives, Oral, Combined; Ethinyl Estradiol; Female; Humans; Menstrual Cycle; Pregnancy; Progesterone Congeners; Randomized Controlled Trials as Topic | 2002 |
An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen.
Topics: Adolescent; Adult; Androstenes; Blood Pressure; Body Weight; Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Ethinyl Estradiol; Female; Humans; Lipids; Menstruation Disturbances; Mineralocorticoid Receptor Antagonists; Patient Compliance; Progesterone Congeners; Surveys and Questionnaires; Uterine Hemorrhage | 2000 |
Yasmin--an oral contraceptive with a new progestin.
Topics: Acne Vulgaris; Androstenes; Body Weight; Contraceptive Agents; Contraceptives, Oral, Combined; Female; Humans; Mineralocorticoid Receptor Antagonists; Progesterone Congeners; Progestins; Thromboembolism; Venous Thrombosis; Weight Gain | 2002 |